Trial reportHepatology (Baltimore, Md.)2012
Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial.
Trial report in Hepatology (Baltimore, Md.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation
Correlation and Comparison of the HepQuant® Disease Severity Index (DSI) With Hepatic Venous Pressure Gradient (HVPG)
Pilot Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
HepQuant: Pilot Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
Who cites it
35 citing papers in PubMed, 76 citations in OpenAlex.
- Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy.BMC gastroenterology · 2020Trial
- Comment on "Hepatic arterial infusion chemotherapy combined with lenvatinib and programmed death receptor-1 inhibitors for hepatocellular carcinoma with Vp4 portal vein tumor thrombus: a multicenter, propensity-score matching comparative study".Hepatology international · 2026Article
- Hepatic cholate clearance as assessed by HepQuant-SHUNT is associated with clinical outcomes in individuals with Fontan circulation.International journal of cardiology. Congenital heart disease · 2026Article
- Evidence Supporting Utility of the Oral Cholate Challenge Test of Liver Function and Physiology to Aid Clinical Management: A Review of Analytical and Clinical Validation Studies.Gastro hep advances · 2026Review
- The causal relationship between platelet indices and liver cancer: a bidirectional two-sample Mendelian randomization study.Discover oncology · 2025Article
- Alterations in Liver Perfusion in Adults With Fontan Circulation as Assessed by Dual Cholate Clearance.Journal of the American Heart Association · 2025Observational
- Measuring the risk of clinical adverse events (RISK ACE) by quantifying liver function: A patient-centric model.European journal of internal medicine · 2025Article
- The Cholate Challenge Test Quantified Baseline Functional Heterogeneity and Improvement in Response to Resmetirom in MASH-related Child-Pugh A Cirrhosis.Gastro hep advances · 2025Article
- Cholate Shunt, Oral Cholate Challenge and Endoscopic Lesions of Portal Hypertension: The SHUNT-V Study.Alimentary pharmacology & therapeutics · 2025Article
- Liver function and portal-systemic shunting quantified by the oral cholate challenge test and risk for large oesophageal varices.Alimentary pharmacology & therapeutics · 2024Article
- Advances in noninvasive measurement of liver function and physiology: The HepQuant DuO test.Basic & clinical pharmacology & toxicology · 2024Article
- The Oral Cholate Challenge Test Quantifies Risk for Liver-Related Clinical Outcomes in Primary Sclerosing Cholangitis.Gastro hep advances · 2024Article
- Liver injury and recovery following radiation therapy for hepatocellular carcinoma: insights from functional liver imaging.Hepatoma research · 2024Article
- Cost-effectiveness of an oral cholate challenge test for the management of patients at risk for large esophageal varices.PloS one · 2024Article
- Causal associations between platelet count, alcohol consumption, and the risk of liver hepatocellular carcinoma based on a Mendelian randomization study.Frontiers in endocrinology · 2024Article
- Role of Lymphotoxin-α Gene Polymorphism in Hepatitis C Virus-Related Chronic Liver Disorders.Infection and drug resistance · 2021Article
- Liver-related effects of chronic hepatitis C antiviral treatment.World journal of gastroenterology · 2020Review
- A Comprehensive Review of Outcome Predictors in Low MELD Patients.Transplantation · 2020Review
- Body composition predicts mortality and decompensation in compensated cirrhosis patients: A prospective cohort study.JHEP reports : innovation in hepatology · 2020Article
- Factors associated with disease progression and viral replication in patients with chronic hepatitis B virus infection.Experimental and therapeutic medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 1 country.
Funding
Abstract
unlabelledRisk for future clinical outcomes is proportional to the severity of liver disease in patients with chronic hepatitis C virus (HCV). We measured disease severity by quantitative liver function tests (QLFTs) to determine cutoffs for QLFTs that identified patients who were at low and high risk for a clinical outcome. Two hundred and twenty-seven participants in the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis (HALT-C) Trial underwent baseline QLFTs and were followed for a median of 5.5 years for clinical outcomes. QLFTs were repeated in 196 patients at month 24 and in 165 patients at month 48. Caffeine elimination rate (k(elim)), antipyrine (AP) clearance (Cl), MEGX concentration, methionine breath test (MBT), galactose elimination capacity (GEC), dual cholate (CA) clearances and shunt, perfused hepatic mass (PHM), and liver and spleen volumes (by single-photon emission computed tomography) were measured. Baseline QLFTs were significantly worse (P = 0.0017 to P < 0.0001) and spleen volumes were larger (P < 0.0001) in the 54 patients who subsequently experienced clinical outcomes. QLFT cutoffs that characterized patients as "low" and "high risk" for clinical outcome yielded hazard ratios ranging from 2.21 (95% confidence interval [CI]: 1.29-3.78) for GEC to 6.52 (95% CI: 3.63-11.71) for CA clearance after oral administration (Cl(oral)). QLFTs independently predicted outcome in models with Ishak fibrosis score, platelet count, and standard laboratory tests. In serial studies, patients with high-risk results for CA Cl(oral) or PHM had a nearly 15-fold increase in risk for clinical outcome. Less than 5% of patients with "low risk" QLFTs experienced a clinical outcome.
conclusionQLFTs independently predict risk for future clinical outcomes. By improving risk assessment, QLFTs could enhance the noninvasive monitoring, counseling, and management of patients with chronic HCV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.